Compass Therapeutics (CMPX) Return on Sales (2024 - 2025)
Compass Therapeutics' (CMPX) quarterly Return on Sales came in at 0.78% in Q2 2025, down 63.0% year-on-year from 2.11% in Q2 2024, and down 26.27% quarter-over-quarter from 0.62% in Q4 2024.
Compass Therapeutics (CMPX) Return on Sales (2024 - 2025) Analysis & Trends
Compass Therapeutics has disclosed Return on Sales across 2 years of filings, most recently posting 0.78% for Q2 2025.
- Return on Sales for Q2 2025 came in at 0.78%, down 63.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 0.78% (down 23.0% YoY), and the FY2024 annual result was 0.67%, changed N/A from the prior year.
- Return on Sales came in at 0.78% for Q2 2025 at Compass Therapeutics, down from 0.62% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.15% in Q2 2024 to a low of 0.78% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Compass Therapeutics | 387.71 Mn | 193.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -0.78% |
| Dec 31, 2024 | -0.62% |
| Sep 30, 2024 | -0.58% |
| Jun 30, 2024 | -0.15% |